The 7.7 magnitude earthquake rattled much of Southeast Asia on Friday. A powerful 7.7 magnitude earthquake rattled much of Southeast Asia on Friday, resulting in mounting casualties and flattened ...

Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...

Kantar's research shows 31 per cent of Canadians surveyed said their taste in food had changed since being on the drug. In the U.S., notable numbers of GLP-1 patients are skipping processed food or ...

This article highlights the impact of diabetes on the community, with 13% of adults in Florence County living with the ...

Medicare will pay an average of 36 percent less for 15 of its most expensive prescription drugs starting in 2027, the U.S. health plan said ...

The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...

Novo Nordisk NOVO.B-1.06%decrease; red down pointing triangle filed for U.S. approval of a higher dose of its Wegovy weight-loss injection, with a decision expected within a month or two. The Danish ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription drugs, including popular weight-loss medications Ozempic and Wegovy, asthma ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

Trump and Novo struck a deal earlier this month that Medicare would pay $245 per month for Ozempic and Wegovy under the administration’s attempt to lower US drug costs by tying them to international ...

The Trump administration negotiated lower prices on 15 costly drugs under Medicare, including Ozempic and Wegovy.

The new prices will take effect in 2027, and the negotiated prices include a monthly cost of $274 for Novo Nordisk’s (NYSE: NVO) popular GLP-1 drug, semaglutide, sold as Wegovy, Ozempic, and Rybelsus.